Search Results 211-220 of 13417 for Relaxin-2
Cohort 3 includes (1) CMVpp65 absent and (2) CMVpp65 present GBM.. Patients in all subcohorts except 1.11 and 1.12 currently have unresectable advanced or ...
DESTINY-Endometrial01: A Phase III Study Of Trastuzumab Deruxtecan Plus Rilvegostomig Or Pembrolizumab As First-Line Treatment Of HER2-Expressing (IHC 3+/2+), ...
... (2) Cohort 2 focuses on primary or secondary myelofibrosis (MF) displaying mutated calreticulin (muCALR); (3) Cohort 3 focuses on glioblastoma multiforme ...
The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in recurrent glioblastoma as ...
More than two thirds of affected infants have other birth defects that include other parts of the gastrointestinal tract, airway, heart, skeleton, kidneys, eyes ...
... 2 dose (RP2D) for future study after treatment with SONALA-001 in combination ... Go to page 22 · Go to page 33 · Go to page 44 · Go to page 55 · NextNext Page.
... two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL. ROF2181. Rochester, Minn., Scottsdale/Phoenix, Ariz ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.